Genetic risk scores fail to predict survival after diagnosis
New research across seven global biobanks shows that the DNA driving disease onset does not determine survival; instead,…
Health Canada approves Ozempic® to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease
Ozempic® is the first-and-only medication indicated for both the once-weekly treatment of adult patients with type 2 diabetes…
Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
Unicycive Therapeutics, Inc. – The U.S. Food and Drug Administration (FDA) identified deficiencies at a third-party manufacturing vendor…